相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Hand Grip Strength Predicts Mortality and Quality of Life in Heart Failure: Insights From the Singapore Cohort of Patients With Advanced Heart Failure
Kathy Z. Dai et al.
JOURNAL OF CARDIAC FAILURE (2023)
Progress Against Cancer Mortality 50 Years After Passage of the National Cancer Act
Tyler B. Kratzer et al.
JAMA ONCOLOGY (2022)
Burden of Pancreatic Cancer: From Epidemiology to Practice
Natalia Khalaf et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Associations of low hand grip strength with 1 year mortality of cancer cachexia: a multicentre observational study
Mengmeng Song et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2021)
MT-102 prevents tissue wasting and improves survival in a rat model of severe cancer cachexia
Mareike S. Poetsch et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2020)
Establishment and characterization of a novel murine model of pancreatic cancer cachexia
Katherine A. Michaelis et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2017)
Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial)
Andrew J. Stewart Coats et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2016)
The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats
Mareike S. Poetsch et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2014)
The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design
Andrew J. Stewart Coats et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2011)
Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with lewis lung carcinoma cells
Josep M. Argiles et al.
MUSCLE & NERVE (2008)